Catalog No.
Product Name
Application
Product Information
Citations
-
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-Me-N-Boc-7-aminoheptanoic acid serves as a bifunctional linker that facilitates the development of E3 ligase ligand-conjugates. Its primary role is to enable the synthesis of targeted protein degradation agents, specifically PROTAC dTAGV-1 TFA. This reagent is essential in studies focused on protein regulation and degradation pathways, contributing to advances in therapeutic development and cellular research. -
E3 Ligase Ligand-linker Conjugate
CBP-IN-1 acid is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTACs, including the potent CBP/p300 degrader, CBPD-268. This compound exhibits significant anti-cancer activity by facilitating the targeted degradation of CBP/p300 proteins. It serves as a valuable tool for researchers exploring targeted protein degradation and its implications in cancer therapies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C11-acid is a synthesized E3 ligase ligand-linker conjugate that targets cereblon, a substrate receptor for E3 ligases. This compound is designed for use in PROTAC (proteolysis-targeting chimera) technology and facilitates the targeted degradation of proteins through the ubiquitin-proteasome system. It serves as a valuable tool for research into proteostasis and potential therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-amine-C11-acid is an E3 ligase ligand-linker conjugate that facilitates targeted protein degradation through the recruitment of E3 ligases. This compound combines Thalidomide with a C11 linker, enabling the synthesis of novel degron compounds such as JQAD1. It is valuable in research applications focusing on protein modulation and the study of E3 ligase interactions. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 39 is a conjugate designed for targeting E3 ligases, specifically integrating a Thalidomide moiety with a linker component. This compound functions as a Cereblon ligand, facilitating the recruitment of the CRBN protein, thereby serving as a critical intermediate in the synthesis of complete proteolysis-targeting chimera (PROTAC) molecules. It is pivotal for researchers developing targeted protein degradation strategies in various biological contexts. -
E3 Ligase Ligand-Linker Conjugate
Phthalimidinoglutarimide-piperidine-NH-Boc is a conjugate designed as an E3 ligase ligand-linker, featuring Thalidomide as its structural backbone. This compound functions as a Cereblon ligand, facilitating the recruitment of the CRBN protein. It serves as a crucial intermediate in the synthesis of complete PROTAC molecules, advancing research in targeted protein degradation and therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugates Chemical
cIAP1 Ligand-Linker Conjugates 16 is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTACs (proteolysis-targeting chimeras). This compound facilitates targeted protein degradation through ubiquitination, making it a valuable tool in chemical biology research. Its application can advance the understanding of protein regulation and potential therapeutic strategies in various diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG4-C2-NH2 is a specialized E3 ligase ligand-linker conjugate that leverages the Thalidomide-derived cereblon ligand for targeted protein degradation. This compound features a PEG4 linker that enhances solubility and stability, facilitating its application in PROTAC technology. It is a valuable tool for researchers investigating targeted protein degradation pathways and the modulation of E3 ligase activity in therapeutic contexts. -
E3 Ligase Ligand- Linker Conjugate
Thalidomide-O-amido-C11-COOH is an E3 ligase ligand and a linker conjugate for CRBN (Cereblon). This compound facilitates the synthesis of PROTACs designed to promote the degradation of DOT1L. Its unique structure allows for targeted protein degradation, making it a valuable tool for research in cellular regulation and therapeutic development. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-cyclohexane is an E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation. By engaging E3 ubiquitin ligases, it enhances the ubiquitination process, promoting proteasomal degradation of specific proteins. This compound is primarily utilized in research applications focused on protein turnover and degradation pathways, providing valuable insights into cellular regulation and therapeutic targets. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-linker Conjugate 140 is specifically designed as a ligand-linker conjugate targeting E3 ubiquitin ligases. This compound serves as a valuable intermediate for the synthesis of PROTAC AR Degrader-6, facilitating the selective degradation of target proteins via the ubiquitin-proteasome pathway. Its applications are vital in the fields of targeted protein degradation and gene regulation research. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-C11-azide is a synthetic E3 ligase ligand-linker conjugate designed for the development of proteolysis-targeting chimeras (PROTACs). This compound facilitates the synthesis of BRD3 degrader-1, enabling targeted degradation of specific proteins via the ubiquitin-proteasome pathway. It serves as a valuable tool in drug discovery and functional studies of protein degradation mechanisms. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 91 is a conjugate composed of an E3 ligase ligand and a linker, featuring (S,R,S)-AHPC, a von Hippel-Lindau (VHL) ligand that effectively recruits VHL proteins. This compound serves as a crucial intermediate in the development of complete PROTAC (proteolysis-targeting chimera) molecules, enabling targeted protein degradation. Its application is significant in the exploration of innovative therapeutic strategies within chemical biology and drug discovery. -
E3 Ligase Ligand-linker Conjugate
Lenalidomide-5-Br-amide-C2-Br is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound can be utilized to synthesize the PROTAC DDR1 degrader-1, facilitating the selective degradation of DDR1 proteins in research studies. Its specific mechanism enhances the efficacy of targeted therapy strategies by leveraging the ubiquitin-proteasome pathway, making it a valuable tool for investigating protein dynamics and function. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide 5-azetidine-2C-oxotetrahydropyrimidin-bromophenyl is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound serves as a key building block for the synthesis of PROTAC GSPT1 degrader-1, enabling selective degradation of the target protein. It is useful in studies aimed at elucidating protein function and developing novel therapeutic strategies through targeted ubiquitination pathways. -
E3 Ligase Ligand-Linker Conjugate
KB02-amide-PEG2-C2-acid is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTACs (proteolysis-targeting chimeras). This compound facilitates targeted protein degradation by enabling the recruitment of E3 ligases to specific substrates. Its applications extend to drug discovery and development, particularly in addressing diseases linked to protein dysregulation. Researchers can utilize this reagent to investigate novel therapeutic strategies through targeted protein modulation. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 5 is a conjugate of Thalidomide and a specific linker, designed to engage E3 ligase pathways. By functioning as a Cereblon ligand, it facilitates the recruitment of CRBN protein. This compound serves as a crucial intermediate for the development of complete PROTAC molecules, providing valuable insights into targeted protein degradation and potential therapeutic applications in cancer and other diseases. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 181 is a specialized E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation through the ubiquitin-proteasome pathway. It enables the effective synthesis of MS115, contributing to research in targeted therapeutics and drug development. This compound serves as a valuable tool for investigating protein interactions and modifications in cellular processes. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-CO-C-cyclohexane is an E3 Ligase Ligand-Linker Conjugate designed for targeted degradation applications. This compound facilitates the synthesis of PROTAC SMARCA2/4-degrader-14, enabling selective degradation of SMARCA2 and SMARCA4 proteins. It is suitable for studies focusing on protein homeostasis and targeted protein degradation mechanisms, contributing to advancements in therapeutic interventions for various diseases. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 28 is a conjugate designed to interact specifically with E3 ligases, incorporating Thalidomide and a corresponding linker. This compound serves as a Cereblon ligand, facilitating the recruitment of the CRBN protein. Its primary application lies in the synthesis of complete PROTAC molecules, essential tools for targeted protein degradation studies and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-linker Conjugate 7 is a conjugate consisting of a Thalidomide-derived E3 ligase ligand and a specific linker. This compound functions primarily by recruiting the Cereblon (CRBN) protein, making it a critical intermediate in the synthesis of complete proteolysis-targeting chimeras (PROTACs). It is ideal for applications in targeted protein degradation research and the development of innovative therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-CH2-CO-NH-C2-PEG2-NH-Boc is an E3 ligase ligand-linker conjugate that incorporates a thalidomide-based cereblon ligand and a PEG linker. This compound serves as a critical building block for the development of PROTAC degraders, facilitating targeted protein degradation. Its utility in chemical biology and drug discovery is significant, particularly in studies aimed at elucidating protein function and therapeutic responses. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG1-OTs is a conjugate designed as a ligand for E3 ligases, facilitating targeted protein degradation. This compound serves as a versatile building block for the synthesis of various targeted degradation compounds, including YD54. Its application in chemical biology and drug discovery makes it a valuable tool for investigating E3 ligase-mediated pathways. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-PEG3-NH2 dihydrochloride is an E3 ligase ligand-linker conjugate designed for use in PROTAC technology. This compound features the (S,R,S)-AHPC ligand, which selectively targets von Hippel-Lindau (VHL) E3 ligases, and is equipped with a three-unit polyethylene glycol (PEG) linker to enhance solubility and target specificity. It is suitable for facilitating the degradation of target proteins in research applications related to protein homeostasis and therapeutic development. -
E3 Ligase Ligand-linker Conjugate
Thalidomide-6-F-5-pip-CHO is a synthetic E3 ligase ligand-linker conjugate designed for the development of proteolysis targeting chimeras (PROTACs). This compound serves as a key component in the synthesis of targeted protein degraders, enabling selective modulation of protein levels within cells. Its application extends to studies in targeted therapy and drug discovery, facilitating innovative approaches in cancer research and beyond. -
Ligand for E3 Ligase
Pomalidomide-CO-C5-azide is a bioorthogonal ligand designed for E3 ligase interaction. This compound enables the synthesis of proteolysis-targeting chimeras (PROTACs), which demonstrate promising anticancer activity. It serves as a valuable tool for researchers developing targeted therapies that utilize the ubiquitin-proteasome system to selectively degrade oncogenic proteins. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-C4-NH2 is an E3 ligase ligand-linker conjugate that features a Pomalidomide-derived cereblon ligand attached to a versatile linker for use in PROTAC technology. This compound facilitates targeted protein degradation by recruiting E3 ligases, enabling the selective degradation of proteins involved in various diseases. Its application in research may enhance the development of innovative therapeutic strategies and provide insights into protein regulation mechanisms. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 50 is a conjugate comprising an E3 ligase ligand, (S,R,S)-AHPC, and a corresponding linker. The (S,R,S)-AHPC is derived from the VH032 structure and functions as a selective ligand for von Hippel-Lindau (VHL) proteins, facilitating targeted protein degradation. This conjugate serves as a crucial intermediate in the synthesis of complete PROTAC molecules, enabling applications in drug discovery and development aimed at modulating protein levels in various biological systems. -
E3 Ligase Ligand-Linker Conjugate
E3 ligase Ligand 29-azacyclohexane-O-cyclohexane-CO is a synthetic E3 ligase ligand-linker conjugate designed for the development of PROTACs. It facilitates the synthesis of PROTAC LRRK2 Degrader-3, a potent degrader of LRRK2 that exhibits significant anti-neuroinflammatory properties. This compound is essential for research applications focused on targeted protein degradation and neuroinflammatory pathways. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-PEG6-Tos is an E3 ligase ligand-linker conjugate that combines a von Hippel-Lindau (VHL)-recruiting ligand with a PEGylated linker featuring a tosyl group. The tosyl moiety serves as a proficient leaving group for nucleophilic substitution reactions. This compound is particularly valuable for the synthesis of PROTAC (Proteolysis Targeting Chimeras) compounds, facilitating targeted protein degradation in various research applications. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-Me-CO-C2-COOH is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound incorporates a VHL ligand with a linker structure derived from (S,R,S)-AHPC, facilitating the development of Proteolysis Targeting Chimeras (PROTACs). Its primary utility lies in enabling specific ubiquitination of target proteins for research into protein regulation and degradation pathways. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-acetylene-C2-OH is an E3 ligase ligand-linker conjugate that combines a cereblon (CRBN) ligand with a flexible linker. This compound facilitates the synthesis of proteolysis-targeting chimeras (PROTACs), enabling targeted protein degradation in various biological systems. Its unique structure supports studies in protein homeostasis and therapeutic applications in cancer research and beyond. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-Me-C4-NH2 hydrochloride is an E3 ligase ligand-linker conjugate designed to enhance protein degradation pathways. It features a VHL ligand and a customized linker based on (S,R,S)-AHPC structure. This compound is suitable for the synthesis of PROTACs, facilitating targeted protein degradation research and applications in drug development. -
E3 Ligase Ligand-Linker Conjugates
E3 Ligase Ligand-linker Conjugate 132 is an intermediary conjugate composed of an E3 ligase ligand and a linker, designed for the synthesis of PROTAC molecules. This compound facilitates targeted protein degradation, offering insights into the modulation of protein levels in cellular systems. Its primary research applications include enhancing the understanding of protein-protein interactions and developing novel therapeutic strategies in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-azacyclohexane is an E3 ligase ligand-linker conjugate that features a CRBN-based ligand critical for targeted protein degradation. This compound is designed for the synthesis of PROTACs, enabling selective modulation of protein levels in cellular systems. Its unique structure supports research into targeted therapies and the mechanistic understanding of protein regulation in various biological contexts. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-5-bromopentanamide is an E3 ligase ligand-linker conjugate that combines the CRBN ligand Lenalidomide with a 5-bromopentanoyl linker. This compound is essential for the synthesis of PROTACs, which facilitate targeted protein degradation in cellular systems. Its application is pivotal in drug discovery and development, particularly in exploring the therapeutic potential of novel degraders in various diseases. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-acetylene-piperidine is an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN)-based ligand with a linker structure. This compound is designed for the synthesis of proteolysis-targeting chimeras (PROTACs), thereby enabling targeted protein degradation in cellular systems. It is valuable for investigative studies aimed at elucidating cellular mechanisms and developing novel therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-C5-NH2 hydrochloride is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound integrates a VHL ligand with a (S,R,S)-AHPC-based linker, facilitating the synthesis of PROTAC molecules. Its unique design enables efficient engagement with E3 ligases, making it a valuable tool for researchers investigating innovative therapeutic strategies in the realm of targeted protein modulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide 5-pyrrolidine-CHO is a conjugate designed for E3 ubiquitin ligase ligand-linker applications. This compound facilitates protein degradation by linking to E3 ligases, enabling targeted protein modulation. It serves as a valuable tool in the development and synthesis of novel bivalent degraders, such as NRX-0492. Researchers can utilize this compound for studies related to targeted therapeutics and protein homeostasis regulation. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-piperidine-C-OH is an E3 ligase ligand-linker conjugate designed to target cereblon (CRBN). This compound facilitates the synthesis of PROTACs (Proteolysis Targeting Chimeras) by linking target proteins to the E3 ligase, promoting targeted degradation. Its key biological activity enhances protein modulation and offers significant potential for therapeutic applications in various diseases, including cancer. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide 5-fluoride 6-piperidine-C-OH is an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN)-based ligand with a functional linker. This compound is utilized in the synthesis of PROTACs, enabling targeted protein degradation through the modulation of E3 ligase activity. Its unique structure facilitates the development of novel therapeutic agents in cellular and molecular biology research. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-5-(PEG2-amine) is an E3 ligase ligand-linker conjugate designed for use in the development of PROTACs (Proteolysis Targeting Chimeras). The compound features a terminal amine group that can undergo reaction with NHS esters or carboxylic acids in the presence of coupling agents such as EDC or HATU. The inclusion of a PEG spacer enhances the hydrophilicity and solubility in aqueous environments, making it suitable for biochemical applications and studies focused on targeted protein degradation. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-C2-amide-C4-Br is an E3 ligase ligand-linker conjugate that incorporates a Pomalidomide-based ligand targeting cereblon (CRBN). This compound is utilized in the synthesis of PROTACs (proteolysis-targeting chimeras), enabling targeted protein degradation and advancing studies in cellular regulation and therapeutic development. The incorporation of the linker facilitates the conjugation of E3 ligase components for efficient protein modulation. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-piperidine-C-piperazine hydrochloride is an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN)-based ligand and a suitable linker. It is designed for the synthesis of PROTAC (Proteolysis Targeting Chimeras), enabling targeted degradation of specific proteins within the cell. This compound demonstrates significant potential in the fields of targeted protein degradation research and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperidin-O-piperidin TFA is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTAC (proteolysis-targeting chimeras). This compound features a CRBN-based ligand linked to a piperidine moiety, facilitating targeted protein degradation. It serves as a valuable tool in chemical biology and drug discovery, particularly for studying protein regulation and therapeutic modulation of disease-related proteins. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-azetidine-CH2-piperazine-C-COOH is an E3 ligase ligand-linker conjugate featuring a CRBN-based ligand and a versatile linker. This compound is designed for the synthesis of Proteolysis Targeting Chimeras (PROTACs), facilitating the selective degradation of target proteins. It enables research into targeted protein degradation mechanisms, offering insights for therapeutic developments. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-5-piperazine-azetidine TFA is an E3 ligase ligand-linker conjugate featuring a cereblon (CRBN)-based ligand and a piperazine-azetidine linker. It is designed for applications in the synthesis of proteolysis-targeting chimeras (PROTACs). This compound facilitates targeted protein degradation by recruiting E3 ligases, making it valuable for research in drug development and molecular biology studies focused on elucidating protein regulation and interactions. -
E3 Ligase Ligand-Linker Conjugates
Me-(S,R,S)-AHPC-PEG2-OTs is a conjugate designed for E3 ligase targeting within E3 Ligase Ligand-Linker Conjugates. This reagent facilitates the synthesis of PROTAC HIF-1α degrader-1, enabling studies in targeted protein degradation and cellular signaling pathways. Its application is essential for research focused on modulating protein levels through proteolysis-targeting chimera technology. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-propargyl-MeOH is an E3 ligase ligand-linker conjugate featuring a cereblon (CRBN) ligand and a propargyl linker. This compound is designed for the synthesis of PROteolysis TArgeting Chimeras (PROTACs), facilitating targeted protein degradation. Its application in biochemical research enables the investigation of protein dynamics and potential therapeutic interventions in various diseases. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide 5'-piperazine-C1-piperidine hydrochloride is an E3 ligase ligand-linker conjugate targeting the cereblon (CRBN) protein. This compound facilitates the design and synthesis of PROTAC (Proteolysis Targeting Chimeras), which are valuable tools for targeted protein degradation research. Its unique properties enable scientists to investigate proteostasis and therapeutic strategies in various biological contexts.
